Drug Discovery Management

BC-1500 Level 1 Pharmaceuticals & Life Sciences 8 providers 21 API surfaces 1 rated strong or better

Target identification, hit-to-lead, lead optimisation.

Drug Discovery Management (BC-1500) is a level-1 business capability in the Pharmaceuticals & Life Sciences model. The catalog holds 21 API surface(s) from 8 provider(s) that can perform some part of it, 1 of them rated strong or better. Reach is the vendor surface that lands on this capability — it is not a claim about what any particular organisation has deployed.

Where this capability definition comes from. This capability is part of a published business-architecture model that API Evangelist did not author. It is redistributed here under CC-BY-4.0. Turbo EA Capabilities by Vincent Verdet — Turbo EA, https://github.com/vincentmakes/turbo-ea-capabilities, CC BY 4.0 Changes: Consolidated from 333 per-L1 YAML files into one JSON; English only (upstream i18n/ omitted); descriptions whitespace-normalised. No capability was added, removed, renamed or re-parented. Source repository · NOTICE and third-party framework attributions

Sub-capabilities

Target Identification & Validation Management BC-1500.10

Disease biology, target identification, target validation.

1 provider, 1 API surface

Hit Discovery Management BC-1500.20

High-throughput screening, virtual screening, hit identification.

1 provider, 2 API surfaces

Lead Optimisation Management BC-1500.30

Medicinal chemistry, SAR, lead optimisation.

1 provider, 1 API surface

Pre-Clinical Candidate Selection Management BC-1500.40

Candidate selection, IND-enabling studies.

no catalog coverage

Translational Research Management BC-1500.50

Translational science, biomarker development.

no catalog coverage

Compound & Library Management BC-1500.60

Compound libraries, samples, repository management.

4 providers, 12 API surfaces

Providers that reach this capability

Ordered by rating band. Reach means a provider publishes an API surface that can perform some part of this capability — it is not a claim that any particular organisation has deployed it.

Exemplar 1 Complete, well-documented, and agent-ready
BenchlingBoxesContainerContainersMolecule5 APIs69.4
Developing 5 Usable, with meaningful gaps to close
BoltzPredictionsProteinSmall Molecule3 APIs50.4PatsnapChemical SAR Extract1 API48.9DynoRuns1 API48.3CenevoCompound Parent StructuresCompoundsPlasmids3 APIs43.9LabguruCompound Parent StructuresCompounds2 APIs42.5
Thin 1 Limited public surface area
ChEMBLActivityAssayCompound RecordMolecule5 APIs33.5
Emerging 1 Early or largely undocumented
piscesCSMPredict1 API24.7
This page carries no rating. Capabilities are not rated. A capability is a description of what a business does, not a thing a company publishes, so a Kin Score would have nothing to measure.
The edge table is a Pro feature. This page shows which providers and tags reach Drug Discovery Management. The underlying tag → capability edges — each with the quoted fragment of the provider's own OpenAPI that evidences it, a calibrated confidence score, and the contract-provenance gate it passed — are available through the API, along with company-level capability maps. Only edges at confidence ≥ 0.7 with evidence found verbatim in the source contract are published at all.

See plans →  ·  How the edges are graded →